Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection-Reference-Cited by-同舟云学术

Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection

Published:2018-05-14 Issue:1 Volume:68 Page:380-383
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Doi Akira¹,Hikita Hayato¹^ORCID,Sakamori Ryotaro¹,Tahata Yuki¹,Kai Yugo¹,Yamada Ryoko¹,Yakushijin Takayuki²,Mita Eiji³,Ohkawa Kazuyoshi⁴,Imai Yasuharu⁵,Furuta Kunimaro¹,Kodama Takahiro¹,Tatsumi Tomohide¹,Takehara Tetsuo¹

Affiliation:

1. Department of Gastroenterology and Hepatology; Osaka University Graduate School of Medicine; Suita Japan

2. Department of Gastroenterology and Hepatology; Osaka General Medical Center; Osaka Japan

3. Department of Gastroenterology and Hepatology, National Hospital Organization; Osaka National Hospital; Osaka Japan

4. Department of Hepatobiliary and Pancreatic Oncology; Osaka International Cancer Institute; Osaka Japan

5. Ikeda Municipal Hospital; Ikeda Japan

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.29836/fullpdf

Reference4 articles.

1. Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment;Kai;Sci Rep,2017

2. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir;Wang;Antimicrob Agents Chemother,2013

3. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens;Akuta;J Med Virol,2017

4. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir;Wyles;J Hepatol,2017

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ledipasvir/Sofosbuvir is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir;Internal Medicine;2023

2. Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan;Journal of Clinical Medicine;2021-11-26

3. Treatment progress and expansion in Japan: From interferon to direct-acting antiviral;Global Health & Medicine;2021-10-31

4. Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection;Clinical Journal of Gastroenterology;2020-07-12

5. Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all‐oral direct antiviral therapy;Hepatology Research;2020-04